新型嘧啶基磺酰胺衍生物作为GPR17调节剂
Novel Pyrimidinyl Sulfonamide Derivatives as GPR17 Modulators.
作者信息
Zhao Taoqian, Liang Steven H
机构信息
Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia 30322, United States.
出版信息
ACS Med Chem Lett. 2025 Jan 27;16(3):361-362. doi: 10.1021/acsmedchemlett.5c00012. eCollection 2025 Mar 13.
Abstract
The present invention relates to novel pyrimidinyl sulfonamide derivatives represented by formula I. These compounds are specifically designed to bind to and modulate GPR17 activities, making them particularly promising for treating diseases associated with GPR17 antagonism.
摘要
本发明涉及由式I表示的新型嘧啶基磺酰胺衍生物。这些化合物经过专门设计，可与GPR17结合并调节其活性，使其在治疗与GPR17拮抗作用相关的疾病方面具有特别的前景。
相似文献
1
Novel Pyrimidinyl Sulfonamide Derivatives as GPR17 Modulators.新型嘧啶基磺酰胺衍生物作为GPR17调节剂
ACS Med Chem Lett. 2025 Jan 27;16(3):361-362. doi: 10.1021/acsmedchemlett.5c00012. eCollection 2025 Mar 13.
2
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
3
Characterisation of GPR17-expressing oligodendrocyte precursors in human ischaemic lesions and correlation with reactive glial responses.人类缺血性病变中表达GPR17的少突胶质前体细胞的特征及其与反应性神经胶质反应的相关性
J Pathol. 2025 Feb;265(2):226-243. doi: 10.1002/path.6381. Epub 2024 Dec 20.
4
Mesh versus non-mesh for inguinal and femoral hernia repair.用于腹股沟疝和股疝修补的补片与非补片对比
Cochrane Database Syst Rev. 2018 Sep 13;9(9):CD011517. doi: 10.1002/14651858.CD011517.pub2.
5
Brexanolone, zuranolone and related neurosteroid GABA receptor positive allosteric modulators for postnatal depression.用于产后抑郁症的布雷沙诺龙、祖拉诺龙及相关神经甾体GABA受体正变构调节剂。
Cochrane Database Syst Rev. 2025 Jun 26;6(6):CD014624. doi: 10.1002/14651858.CD014624.pub2.
6
Selective progesterone receptor modulators (SPRMs) for uterine fibroids.用于子宫肌瘤的选择性孕激素受体调节剂（SPRMs）
Cochrane Database Syst Rev. 2017 Apr 26;4(4):CD010770. doi: 10.1002/14651858.CD010770.pub2.
7
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
9
Adapting Safety Plans for Autistic Adults with Involvement from the Autism Community.在自闭症群体的参与下为成年自闭症患者调整安全计划。
Autism Adulthood. 2025 May 28;7(3):293-302. doi: 10.1089/aut.2023.0124. eCollection 2025 Jun.
10
"I Wish They'd Just Let Us Be." Experiences of Indian Autistic Individuals Around Stimming Behaviors at the Workplace.“我希望他们能让我们顺其自然。”印度自闭症患者在工作场所围绕自我刺激行为的经历。
Autism Adulthood. 2024 Dec 2;6(4):474-484. doi: 10.1089/aut.2022.0096. eCollection 2024 Dec.
本文引用的文献
1
Oligodendrocyte Dysfunction in Amyotrophic Lateral Sclerosis: Mechanisms and Therapeutic Perspectives.肌萎缩侧索硬化症中的少突胶质细胞功能障碍：机制和治疗展望。
Cells. 2021 Mar 5;10(3):565. doi: 10.3390/cells10030565.
2
GPR17 receptor modulators and their therapeutic implications: review of recent patents.GPR17 受体调节剂及其治疗意义：近期专利述评。
Expert Opin Ther Pat. 2019 Feb;29(2):85-95. doi: 10.1080/13543776.2019.1568990. Epub 2019 Jan 24.
3
Orphan G protein-coupled receptors: The role in CNS disorders.孤儿 G 蛋白偶联受体：在中枢神经系统疾病中的作用。
Biomed Pharmacother. 2018 Feb;98:222-232. doi: 10.1016/j.biopha.2017.12.056. Epub 2017 Dec 27.
4
Pharmacological Properties and Biological Functions of the GPR17 Receptor, a Potential Target for Neuro-Regenerative Medicine.GPR17 受体的药理学特性和生物学功能，神经再生医学的潜在靶点。
Adv Exp Med Biol. 2017;1051:169-192. doi: 10.1007/5584_2017_92.
5
The G Protein-Coupled Receptor GPR17: Overview and Update.G 蛋白偶联受体 GPR17：概述与更新。
ChemMedChem. 2016 Dec 6;11(23):2567-2574. doi: 10.1002/cmdc.201600453. Epub 2016 Nov 14.
6
CNS remyelination as a novel reparative approach to neurodegenerative diseases: The roles of purinergic signaling and the P2Y-like receptor GPR17.中枢神经系统再髓鞘化作为神经退行性疾病的一种新型修复方法：嘌呤能信号传导和P2Y样受体GPR17的作用
Neuropharmacology. 2016 May;104:82-93. doi: 10.1016/j.neuropharm.2015.10.005. Epub 2015 Oct 8.
7
New members of the chemokine receptor gene family.
J Leukoc Biol. 1996 Jan;59(1):18-23. doi: 10.1002/jlb.59.1.18.
Zotero 插件